Ardelyx (ARDX) Chief Patient Officer receives 82,695 RSUs and 124,040 stock options

Rhea-AI Filing Summary

Ardelyx Chief Patient Officer receives new equity awards. Laura A. Williams reported a grant of 82,695 shares of Ardelyx common stock on January 23, 2026, issued at $0 per share as restricted stock units that convert 1-for-1 into common stock when they vest. She also received a stock option for 124,040 shares of common stock at an exercise price of $7.77 per share, granted at no cost. The option vests in 48 equal monthly installments starting January 23, 2026, conditioned on her continued employment or service. Following these transactions, Williams directly beneficially owned 444,258 shares of Ardelyx common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Laura A

(Last) (First) (Middle)

C/O ARDELYX, INC.

400 FIFTH AVENUE, SUITE 210

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARDELYX, INC. [ ARDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Patient Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		A		82,695(1)	A	$0	444,258	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.77	01/23/2026		A		124,040		(2)	01/23/2036	Common Stock	124,040	$0	124,040	D

Explanation of Responses:

1. Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof.

2. The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 23, 2026, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

	/s/ Elizabeth Grammer, Attorney-in-Fact for Laura A. Williams	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ARDX Chief Patient Officer report?

Laura A. Williams, Chief Patient Officer of Ardelyx (ARDX), reported receiving 82,695 shares of common stock for $0 and a stock option covering 124,040 shares of common stock on January 23, 2026.

What are the terms of the new Ardelyx (ARDX) stock option granted to Laura A. Williams?

The new stock option gives Laura A. Williams the right to buy 124,040 shares of Ardelyx common stock at an exercise price of $7.77 per share. It vests in 48 equal monthly installments starting on January 23, 2026, subject to her continued employment or service.

How do the restricted stock units (RSUs) for ARDX work in this Form 4?

The filing states that the restricted stock units (RSUs) entitle Laura A. Williams to receive one share of Ardelyx common stock for each RSU when the RSUs vest.

How many Ardelyx (ARDX) shares does Laura A. Williams own after these transactions?

After the reported RSU-related acquisition, Laura A. Williams directly beneficially owned 444,258 shares of Ardelyx common stock.

Are the equity awards to the ARDX Chief Patient Officer direct or indirect holdings?

Both the 82,695 common shares and the 124,040-share stock option reported in this Form 4 are listed as direct (D) holdings of Laura A. Williams.

When do the new Ardelyx (ARDX) stock options granted on January 23, 2026 expire?

The stock option granted to Laura A. Williams on January 23, 2026 is shown with an expiration date of January 23, 2036.